MPEP § 2429 — MPEP § 2429
Current through: 2022-07-01

2429-Helpful Hints for Sequence Rules Compliance under WIPO ST.25 
 
 

 
 
 
 
 
 
 
 

 

 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

 Skip over navigation 
 
 
 
 
 
 
 
 search for patents | search for trademarks 

 
 
 
 
 
 
 
 
 
 
 
 Search 
 
 
 

 
 

 
 
 
 
 
 PATENTS 
 
 Patent Search 

 
 Patent Process 

 
 Patent Classification 

 
 Patent Forms 

 
 Statistics 

 
 Electronic Business Center 

 
 Patent Laws, Regulations, Policies & Procedures 

 
 Resources and Guidance 

 
 Office of Data Management 

 
 Announcements 

 
 Initiatives & Events 

 
 International Protection 

 
 Employee Locator 

 
 Contact Patents 

 

 

 
 TRADEMARKS 
 
 Trademark Search 

 
 Trademarks Process 

 
 News & Notices 

 
 Manuals, Guides, Official Gazette 

 
 Laws & Regulations 

 
 Online Filing 

 
 Contact Trademarks 

 

 

 
 IP LAW & POLICY 
 
 Rulemaking 

 
 IP Policy and Enforcement 

 
 Protecting IP Overseas 

 
 Training and Education 

 
 Training Programs & Conferences 

 
 Office of Governmental Affairs 

 
 Office of Chief Economist 

 
 Boards and Counsel 

 

 

 
 PRODUCTS & SERVICES 
 
 Electronic Data Products 

 
 XML Resources 

 
 XML Resources - Retrospective 

 
 USPTO Contact Center Order Form 

 
 Services 

 
 Locate Libraries 

 
 Training/Events 

 
 Online Services Hub 

 

 

 
 INVENTORS 
 
 Patents for Inventors 

 
 Trademarks for Inventors 

 
 Inventors Assistance 

 
 Education and Information 

 
 Scam Prevention 

 
 Pro Se and Pro Bono 

 
 Current Events 

 
 State Resources 

 
 InventorsEye Newsletter 

 

 

 
 NEWS & NOTICES 
 
 Subscription Center 

 
 Press Releases 

 
 Testimony and Speeches 

 
 Director's Forum 

 
 Systems Status 

 
 Emergency Notices 

 
 USPTO Videos 

 
 Official Gazette 

 
 Federal Register Notices 

 
 Event Calendar 

 

 

 
 FAQs 
 
 Patents FAQs 

 
 Trademarks FAQs 

 
 Assignments 

 
 Security 

 
 Musicians and Artists 

 
 Browser Plugins 

 
 Other Web Resources 

 

 

 
 ABOUT US 
 
 USPTO Leadership 

 
 USPTO Organization 

 
 USPTO Offices 

 
 Careers 

 
 Budget, Performance, and Planning 

 
 Statistics 

 
 Vendor Information 

 
 Public Advisory Committees 

 
 National Medal of Technology and Innovation 

 
 IP in Motion 

 
 Contact Us 

 

 

 
 
 

 

 
 

 
 
 
 
 Home Page 

 
 Patents 

 
 Patent Laws, Regulations, Policies & Procedures 

 
 Manual of Patent Examining Procedure 

 Chapter 2400 

 Section 2429 
 

 
 
 
 
 
 2429 Helpful Hints for Sequence Rules Compliance under WIPO ST.25 [R-07.2022]

 [Editor Note: This section is not applicable to applications filed on or after
 July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in
 37 CFR
 1.831(b) . See MPEP §§
 2412 - 2419 for guidance on WIPO ST.26
 requirements for applications filed on or after July 1, 2022.] 

 The Office has the following tips regarding sequence rules in compliance
 with WIPO ST.25.
 

 —Compliance is not a filing date issue. 

 —Compliance is not a 35 U.S.C. 112 issue.
 

 —Compliance is not a 35 U.S.C. 119 / 120 issue.
 

 —Compliance is not per se a new matter issue. The
 standard for resolution of inconsistencies between the “Sequence Listing” (submitted as an
 ASCII plain text file, on read-only optical disc(s), as a PDF image file, or on physical
 sheets of paper pursuant to 37 CFR 1.821(c) ) and a separate
 computer readable form thereof pursuant to 37 CFR 1.821(e) (if required) and/or
 errors in the “Sequence Listing” is based on the new matter standard.
 

 —Compliance can be achieved via amendment. See MPEP § 2426 for
 additional information regarding amendments to add or replace a “Sequence Listing” and CRF
 thereof. See 37 CFR
 1.825 .
 

 —If sequence information is submitted in an application
 filed under 35
 U.S.C. 111(a) or 35 U.S.C. 371 as an ASCII plain text
 file in compliance with 37 CFR 1.824 via the USPTO patent electronic filing system or on
 read-only optical disc(s) and applicant has not filed a “Sequence Listing” as a PDF image
 file or on physical sheets of paper, the ASCII plain text file will serve as both the
 “Sequence Listing” under 37 CFR 1.821(c) and the CRF of the “Sequence Listing” under
 37 CFR
 1.821(e) . See 37 CFR 1.821(e)(1) . Thus, the following
 are not required and should not be submitted: (1) a second copy of the “Sequence Listing”
 as a PDF image file or on physical sheets of paper; and (2) a statement under
 37 CFR
 1.821(e)(1)(ii) or (2)(ii) (indicating that the sequence
 information contained in the “Sequence Listing” under 37 CFR 1.821(c) and CRF copy of the
 “Sequence Listing” under 37 CFR 1.821(e)(1)(ii) or
 37 CFR
 1.21(o) are identical). Any “Sequence Listing” submitted as an ASCII
 plain text file via the USPTO patent electronic filing system or on read-only optical
 disc(s) under 37 CFR
 1.52(e) and in compliance with 37 CFR 1.821(c) will be excluded when
 determining the application size fee required by 37 CFR
 1.16(s) or 37 CFR 1.492(j) as per
 37 CFR
 1.52(f)(1) and (2) . See MPEP §
 2422.03(a) for additional information. See MPEP §
 2422.03(a) for additional information.
 

 —The USPTO encourages applicants to file their patent
 applications via the USPTO patent electronic filing system and imposes a surcharge for
 non-electronic filing of an original patent application (excluding reissue, design, plant,
 and provisional applications). Filing a “Sequence Listing” via USPTO patent electronic
 filing system as a PDF image file or on physical sheets of paper is not recommended. A
 “Sequence Listing” in PDF format or on physical sheets of paper is treated as the “Sequence
 Listing” required by 37
 CFR 1.821(c) and requires filing of both a separate CRF and a
 statement that the “Sequence Listing” and the CRF are identical in an application filed
 under 35 U.S.C.
 111(a) regardless of if the sequence information is also filed as an
 ASCII plain text file, as required by 37 CFR 1.821(e)(1)(ii) , and in a
 national stage application filed under 35 U.S.C. 371 if the sequence
 information is not also filed as an ASCII plain text file, as required by 37 CFR
 1.821(e)(2)(ii) . In addition, a “Sequence Listing” submitted in PDF
 format or on physical sheets of paper as part of the specification is not excluded when
 determining the application size fee required by 37 CFR
 1.16(s) or 1.492(j) . See 37 CFR 1.52(f)(1) and
 (2) .
 

 —For international applications (PCT), the check list of the
 PCT Request filed with the international application must contain an indication that the
 sequence listing, filed with the PCT application on the international filing date forms
 part of the international application. See MPEP §
 2422.03(a) , subsection IV, for information specific to filing
 sequence listings in international applications (PCT) via the USPTO patent electronic
 filing system.
 

 —Applicants are reminded that for fee purposes, a table of
 sequences is not a “Sequence Listing”. Such tables are considered part of the specification
 and are included when determining the application size fee required by 37 CFR 1.16(s) or
 1.492(j) . See 37 CFR 1.52(f)(1) and (2) . 
 

 —Applicants are encouraged to draft their specifications
 such that sequence data that is not essential material is not required to be included in a
 “Sequence Listing”. 37
 CFR 1.21(o) and 1.52(f)(3) provide that the submission
 of an oversized “Sequence Listing” (a mega-“Sequence Listing”) of 300 MB or more are
 subject to additional fees. A mega-“Sequence Listing”, in particular, often include
 sequences that are available in the prior art, are not essential material, and could have
 been described instead, for example, by name and a publication or accession reference.
 

 —Failure to reply to sequence compliance issues in a timely
 manner may reduce any patent term adjustment. Patent applications filed under
 35 U.S.C.
 111(a) on or after December 18, 2013, and international patent
 applications in which the national stage commenced under 35 U.S.C. 371 on or
 after December 18, 2013, may be subject to reductions in patent terms adjustment pursuant
 to 37 CFR
 1.704(c)(13) if they are not in condition for examination within
 eight months from the filing date or date of commencement, respectively. “In condition for
 examination” includes compliance with 37 CFR 1.821 - 1.825 (see
 37 CFR
 1.704(f) ).
 

 —The copy of the “Sequence Listing” required by 37 CFR 1.821(c) is an
 integral part of the application. If submitted as a PDF image file or on physical sheets of
 paper, the “Sequence Listing” must begin on a new page, should appear at the end of the
 application, and preferably should be numbered independently of the numbering of the
 remainder of the application. The new page that begins the “Sequence Listing” should be
 entitled “Sequence Listing.” See 37 CFR 1.823(b)(3) . If not submitted as
 such at filing, the “Sequence Listing” must be inserted into the application via amendment,
 e.g., by preliminary amendment. See 37 CFR 1.825 . If submitted as an ASCII
 plain text file via the USPTO patent electronic filing system or read-only optical disc,
 the specification must contain an incorporation by reference of the material, except for a
 national stage entry under 37 CFR 1.495(b)(1) , where the “Sequence
 Listing” has been previously communicated to the International Bureau or originally filed
 in the USPTO and complies with Patent Cooperation Treaty Rule 5.2 . 
 

 —A replacement “Sequence Listing” must be used to amend a “Sequence
 Listing” regardless of whether the “Sequence Listing” was filed as an ASCII plain text file
 via the USPTO patent electronic filing system, on read-only optical disc(s)
 ( 37 CFR
 1.821(c)(1) , as a PDF file via the USPTO patent electronic filing
 system ( 37
 CFR 1.821(c)(2) , or on physical sheets of paper ( 37 CFR
 1.821(c)(3) . See MPEP § 2426 for additional information
 regarding amendments to add or replace a “Sequence Listing” and CRF copy thereof.
 

 —The practice of computer readable form transfers from one application to
 another has been eliminated.
 

 —Angle brackets and numeric identifiers listed in
 37 CFR
 1.823 and Appendix G to Subpart G of Part 1 of the CFR (reproduced in
 MPEP §
 2424 ) are very important for our database. Extra punctuation
 should not be used in a “Sequence Listing”.
 

 —A “Sequence Listing” ( 37 CFR 1.821(c) ) or a separate CRF of a
 “Sequence Listing” ( 37
 CFR 1.821(e) ) as an ASCII plain text file cannot contain page
 numbers. Page numbers should only be placed on PDF image files or on physical sheets of
 paper of the “Sequence Listing”. 
 

 —The PatentIn computer program is not the only means by which to comply
 with the rules. Any word processing program can be used to generate a “Sequence Listing” if
 it has the capability to convert a file into ASCII plain text. However, use of a word
 processing program to generate or amend a “Sequence Listing” file is discouraged. Word
 processing programs often introduce unintended changes to the “Sequence Listing” that
 render the listing unacceptable. Use of a plain text editor to generate or edit a “Sequence
 Listing” is recommended.
 

 —If a word processing program is used to generate a “Sequence Listing”,
 hard page break controls should not be used and margins should be adjusted to the smallest
 setting.
 

 —Word processing files should not be submitted to the Office; the
 “Sequence Listing” generated by a word processing file should be saved as an ASCII plain
 text file for submission. Most word processing programs provide this feature.
 

 —Statements in accordance with 37 CFR
 1.821(e)(1)(ii) , (e)(2)(ii) , (e)(3)(iii) , and (h) and 37 CFR
 1.825(a)(3) , (a)(4) , (a)(6) ,
 (b)(3) , (b)(4) , (b)(5) ,
 and (b)(7) and proper labeling for read-only optical disc(s) in
 accordance with 37 CFR 1.52(e)(5)(vi) should be noted.
 Sample statements to support filings and submissions in accordance with 37 CFR 1.821 through
 1.825 are provided in MPEP § 2428 Sample Statements.
 

 —Use Box SEQUENCE. See MPEP § 2433 .
 

 —On nucleotide sequences, since only single strands may be depicted in the
 “Sequence Listing”, show strands in 5' to 3' direction from left to right in accordance
 with 37 CFR
 1.822(c)(5) .
 

 —The single stranded nucleotide depicted in the “Sequence Listing” may
 represent a strand of a nucleotide sequence that may be single or double stranded which may
 be, further, linear or circular. An amino acid sequence or peptide may be linear or
 circular. 
 

 —Numeric identifiers “<140>, Current Application Number,”
 “<141>, Current Filing Date,” “<150>, Prior Application Number,” and
 “<151>, Prior Application Filing Date,” should appear in the “Sequence Listing” in
 all cases. If the information about the current application is not known or is unavailable
 at the time of completing the “Sequence Listing”, then the lines following numeric
 identifiers <140> and <141> should be left blank. This would normally be the
 case when the “Sequence Listing” is included in a newly filed application. Similarly, if
 information regarding prior applications is inapplicable, or not known at the time of
 completing the “Sequence Listing” but will be later filed, then the numeric identifiers
 <150> and <151> should appear with the line following the numeric identifiers
 left blank. 
 

 —The mandatory items of information that must be included in a “Sequence
 Listing” are identified in the table of numeric identifiers set forth Appendix G to Subpart
 G of Part 1 of the CFR. See also MPEP § 2424.02 .
 

 —Pursuant to 37 CFR 1.83(a) , sequences that are
 included in a “Sequence Listing” should not be duplicated in the drawings. However,
 significant sequence characteristics that are not readily conveyed by the data in the
 “Sequence Listing” may be depicted in a drawing figure. However, the sequence information
 so conveyed must still be included in a “Sequence Listing” if the sequence falls within the
 definition set forth in 37 CFR 1.821(a) , and the sequence identifier (“SEQ ID NO:X or the
 like”) must be used, either in the drawing or in the “Brief Description of the Drawings.”
 See MPEP §
 2422.02 for additional information. 
 

 —Inosine may be represented by the use of “I” in the features section,
 otherwise use “n.”
 

 —Stop codons that are represented by an asterisk are not permitted in
 amino acid sequences.
 

 —Punctuation should not be used in a sequence to indicate unknown
 nucleotide bases or amino acid residues or to delimit active or functional regions of a
 sequence. These regions should be noted as Features of the sequence per Appendix G to
 Subpart G of Part 1 of the CFR (see numeric identifiers <220> - <223>.
 (Appendix G is reproduced in MPEP § 2424 ).
 

 —The presence of an unnatural amino acid in a sequence does not have the
 same effect as the presence of a D-amino acid. The sequence may still be subject to the
 rules even though one or more of the amino acids is not naturally occurring.
 

 —Cyclic and branched peptides are causing some confusion in the
 application of the rules. Specific questions should be directed to Sequence Systems Service
 Center of the Scientific and Technical Information Center at 571-272-2510. 
 

 —A cyclic peptide with a tail is regarded as a branched sequence, and
 thereby exempt from the rules, if all bonds adjacent to the amino acid from which the tail
 emanates are normal peptide bonds.
 

 —Sequences that have variable-length regions depicted as, for example, Ala
 Ala Leu Leu (Xaa Xaa) n Ile Pro where n=0-234 or
 agccttgggaca(nnnnn) m gtcatt where m=0-354 or Ser Met Ala Xaa Ser
 where Xaa could be 1, 2, 3, 4 and/or 5 amino acids must still comply
 with the Sequence Rules. The method to use is to repeat the variable-length region as many
 times as the maximum length and specify in the Features section that the amino acid (or
 nucleotide) at a specified position is either absent or present. The variables Xaa and n
 may stand for only one residue, hence the need to repeat the variable. The correct way to
 submit the third example is Ser Met Ala Xaa Xaa Xaa Xaa Xaa Ser combined with an
 explanation in the Features section of the listing that any one or all of amino acids 4-8
 can either be present or absent.
 

 —Single letter amino acid abbreviations are not acceptable within the
 “Sequence Listing” but may appear elsewhere in the application.
 

 —Zero (0) is not used when the numbering of amino acids uses negative
 numbers to distinguish the mature protein.
 

 —Subscripts or superscripts are not permitted in a “Sequence Listing”. 

 —The exclusive conformance requirement of 37 CFR 1.821(b) 
 requires that any amendment of the sequence information in a “Sequence Listing” be
 accompanied by an amendment to the corresponding information, if any, embedded in the text
 of the specification or presented in a drawing figure. 
 

 —A mandatory feature is required to cover every “n” or “Xaa”
 used in a sequence. The feature consists of numeric identifiers <220>, <221>,
 <222>, and <223>. Numeric identifier <220> should remain blank, numeric
 Identifier <221> should be selected from Appendices E and F to Subpart G of Part 1 of
 the CFR (reproduced in MPEP
 § 2422 (I)), numeric identifier <222> should identify the
 location of the “n” or “Xaa” within the sequence, and numeric identifier should <223>
 specify what the “n” or “Xaa” can be. When all of the “n” or “Xaa” variables in a sequence
 are equal to the same thing, a range of the entire sequence can be given for numeric
 identifier <222> to cover all of the “n” or “Xaa” designators in one feature.
 

 —Remove all non-ASCII characters from the .txt file. For
 example, an α symbol should be spelled out as “alpha.”
 

 —Tabs are non-ASCII characters. Do not use tabs in “Sequence
 Listing” .txt files.
 

 —Make all explanations in a feature section consistent with
 the molecule type in numeric identifier <212>. For example, if the sequence is type
 “PRT” do not describe the sequence in a feature section as a “synthetic
 oligonucleotide.”
 

 —A response for numeric identifier <130>, “File
 Reference,” is mandatory if the numeric identifier <140> is not present, e.g., when
 the “Sequence Listing” is filed before the application number has been assigned. At least
 one of a numeric identifier <130> with docket number or numeric identifier
 <140> with current application number must be in the “Sequence Listing”. This
 information is used to ensure that ASCII plain text files are correctly matched to their
 corresponding applications. 
 

 —If a “Sequence Listing” is modified by the addition or
 deletion of sequences, remember to update the total number of sequences in numeric
 identifier <160>.
 

 —Numeric identifier <213> can only be one of three
 choices: Scientific name (i.e. Genus/species), Unknown, or Artificial Sequence. Do not add
 any extraneous information about the sequence, such as a gene names, in this field. Do not
 use common names for species. For example, human should be “Homo sapiens” and cow should be
 “Bos taurus.” If a specific genus/species is unknown, use the reply “Unknown” in numeric
 identifier <213> and add whatever information is known into numeric identifier
 <223> of the feature section. For example, if only the family “Saccharomycetaceae” is
 known, numeric identifier <213> should state “Unknown” and numeric identifier
 <223> could state “fungus of the family Saccharomycetaceae.”
 

 —For all sequences using “Unknown” or “Artificial sequence”
 for numeric identifier <213>, a mandatory feature is required to explain the source
 of the genetic material. The feature consists of <220>, which remains blank, and
 <223>, which states the source of the genetic material. To explain the source, if the
 sequence is put together from several organisms, please list those organisms. If the
 sequence is made in the laboratory, please indicate that the sequence is synthesized.
 

 —Only use abbreviations that are specifically defined in
 “WIPO Standard ST.25 (2009)” or that are well known. Do not use abbreviations that are
 specific to the application at issue and would not be clear to someone who had not read the
 invention description. When in doubt, use the full name rather than an abbreviation. 
 

 —Note that if a “Sequence Listing” provided as an ASCII plain
 text file or a separate CRF of a “Sequence Listing” is rejected and an error report issued,
 the errors listed are exemplary and may not be a complete list of all errors in the
 “Sequence Listing” file. The applicant is required to review the “Sequence Listing” in its
 entirety and correct all instances of similar errors.
 

 —Any inquiries regarding a specific “Sequence Listing” provided as an
 ASCII plain text file or a separate CRF of a “Sequence Listing” that has been processed by
 the Office should be directed to the Sequence Systems Service Center of the Scientific and
 Technical Information Center at 571-272-2510.
 

 [top] 

 

 

 
 

 
 

 

 

 

 
 
 
 2401-Introduction 

 2402-The Deposit Rules 

 2403-Deposit of Biological Material 
 2403.01-Material Capable of Self- Replication 

 2403.02-Plant Material 

 
 

 2404-Need or Opportunity to Make a Deposit 
 2404.01-Biological Material That Is Known and Readily Available to the Public 

 2404.02-Biological Material That Can Be Made or Isolated Without Undue Experimentation 

 2404.03-Reference to a Deposit in the Specification 

 
 

 2405-Acceptable Depository 

 2406-Time of Making an Original Deposit 
 2406.01-Description in Application Specification 

 2406.02-Deposit After Filing Date - Corroboration 

 2406.03-Possible Loss of U.S. Filing Date in Other Countries 

 
 

 2407-Replacement or Supplement of Deposit 
 2407.01-In a Pending Application 

 2407.02-After a Patent Has Issued 

 2407.03-Failure to Replace 

 2407.04-Treatment of Replacement 

 2407.05-Exemption From Replacement 

 2407.06-Replacement May Not Be Recognized 

 
 

 2408-Term of Deposit 

 2409-Viability of Deposit 

 2410-Furnishing of Samples 
 2410.01-Conditions of Deposit 

 2410.02-Certification of Statement of Availability of Deposit 

 
 

 2411-Examination Procedures 
 2411.01-Rejections Based on Deposit Issue 

 2411.02-Replies to Rejections Based on Deposit Issue 

 2411.03-Application in Condition for Allowance Except for Deposit 

 2411.04-[Reserved] 

 2411.05-Content of Application with Respect to Deposited Material 

 
 

 2412-The Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures to Include
 a Sequence Listing in XML file format 
 2412.01-Overview of the Sequence Rules 

 2412.02-Definition of “Sequence Listing XML” 
 2412.02(a)-“Enumeration of its residues” 

 
 

 2412.03-Nucleotides and Amino Acids Included and Excluded From a “Sequence Listing XML” 
 2412.03(a)-“Specifically Defined” 

 2412.03(b)-“Amino Acid” 

 2412.03(c)-“Modified Amino Acid” 

 2412.03(d)-“Nucleotide” 

 2412.03(e)-“Modified Nucleotide” 

 
 

 2412.04-Use of Sequence Identifiers to Denote Sequences Disclosed in the Description, Drawings or Claims 

 2412.05-Representation and Symbols for Nucleotide and/or Amino Acid Sequences 
 2412.05(a)-Use of Sequentially Numbered Sequence Identifiers in the “Sequence Listing XML” 

 2412.05(b)-Representation and Symbols of Nucleotide Sequence Data 

 2412.05(c)-Representation and Inclusion of Variants 

 2412.05(d)-Representation and Symbols of Amino Acid Sequence Data 

 2412.05(e)-Presentation of Special Situations 

 
 

 2412.06-The Requirement for Exclusive Conformance; Sequences Presented in Drawing Figures 

 2412.07-Examination of Patent Applications Claiming Large Numbers of Nucleotide Sequences 

 
 

 2413-Content of a “Sequence Listing XML” and Form and Format of the “Sequence Listing XML” File 
 2413.01-Parts of the “Sequence Listing XML” 
 2413.01(a)-The “Sequence Listing XML” is a Single File Encoded Using Unicode UTF-8 

 2413.01(b)-The “Sequence Listing XML” Must Be Valid According To the DTD 

 2413.01(c)-The “Sequence Listing XML” Must Contain an XML Declaration 

 2413.01(d)-The “Sequence Listing XML” Must Contain a DOCTYPE Declaration 

 2413.01(e)-The “Sequence Listing XML” Must Contain a Root Element 

 2413.01(f)-The “Sequence Listing XML” Must Contain a General Information Part 

 2413.01(g)-The “Sequence Listing XML” Must Contain a Sequence Data Part 

 2413.01(h)-Language Dependent Free Text Qualifier Values in the English Language 

 2413.01(i)-Title Element in “Sequence Listing XML” 

 
 

 2413.02-Form and Format of the XML file containing the “Sequence Listing XML” 

 2413.03-How to Submit the “Sequence Listing XML” 

 2413.04-Requirements Regarding Incorporation By Reference of the “Sequence Listing XML” 

 2413.05-Presumptions Regarding Compliance 

 
 

 2414-Notification of a Failure to Comply with Sequence Listing Requirements and Amendments Relating to “Sequence Listing XML” Files
 Under 37 CFR 1.835 
 2414.01-Issuance of a Notice Relating to the Requirements For Patent Applications Containing Nucleotide and/or Amino Acid Sequence
 Disclosures 

 2414.02-Amendment to Add an Initial “Sequence Listing XML” under 37 CFR 1.835(a) 

 2414.03-Amendment Adding to, Deleting from, or Replacing Sequence Information in a “Sequence Listing XML” under 37 CFR 1.835(b) 

 2414.04-Translation of “Sequence Listing XML” is Not an Amended “Sequence Listing XML” under 37 CFR 1.835(b) 

 2414.05-Notifications for Failure to Submit a “Sequence Listing XML” in an International Application under the PCT to be Searched
 by the United States International Searching Authority or Examined by International Preliminary Examination Authority 

 2414.06-Amendment of a “Sequence Listing XML” in a Patent 

 
 

 2415-Applicability date of “Sequence Listing XML” Requirements to Applications Based on Filing Date of Application and Procedures
 for Failure to Submit Correct Format of Sequence Listing 
 2415.01-Determining if a “Sequence Listing XML” Must be Submitted 

 2415.02-Provisional Applications Containing Disclosures of Nucleotides and/or Amino Acids, Compliance with 37 CFR 1.831-1.834 

 2415.03-Improper Submissions of “Sequence Listing” under 1.821(c) When a “Sequence Listing XML” was Required 

 
 

 2416-Form Paragraphs 

 2417-Helpful Hints for Sequence Rules Compliance under WIPO Standard ST.26 

 2418-WIPO Sequence Tool 

 2419-Publishing of Patent Grants and Patent Application Publications with a “Sequence Listing XML” 
 2419.01-Patent Grants and Patent Application Publications Containing a Non-Lengthy “Sequence Listing XML” 

 2419.02-Patent Grants and Patent Application Publications Containing a Lengthy “Sequence Listing XML” 

 2419.03-Patent Grants and Patent Application Publications Containing a “Sequence Listing XML” of 1GB or Larger 

 
 

 2420-The Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures under World
 Intellectual Property Office Standard ST.25 (WIPO ST.25) - the Sequence Rules 

 2421-Overview of the Sequence Rules under WIPO ST.25 
 2421.01-Definition of “Sequence Listing” and Computer Readable Form (CRF) 

 2421.02-Summary of the Requirements of the Sequence Rules 

 2421.03-Notification of a Failure to Comply 

 2421.04-[Reserved] 

 
 

 2422-Nucleotide and/or Amino Acid Sequence Disclosures in Patent Applications Subject to WIPO ST.25 
 2422.01-Nucleotide and/or Amino Acids Disclosures Requiring a “Sequence Listing” 

 2422.02-The Requirement for Exclusive Conformance; Sequences Presented in Drawing Figures 

 2422.03-Sequence Listing Submission 

 2422.03(a)-“Sequence Listing” Submitted as ASCII Plain Text Files 

 2422.04-The Requirement for a Computer Readable Copy of the “Sequence Listing” 

 2422.05-[Reserved] 

 2422.06-Requirement for Statement Regarding Information Contained in the “Sequence Listing” and Separate Computer Readable Form 

 2422.07-Requirements for Compliance and Consequences of Non-Compliance 

 2422.08-Presumptions Regarding Compliance 

 2422.09-[Reserved] 

 
 

 2423-Symbols and Format To Be Used for Nucleotide and/or Amino Acid Sequence Data for WIPO ST.25 
 2423.01-Format and Symbols To Be Used in a “Sequence Listing” 

 2423.02-Depiction of Coding Regions 

 2423.03-Presentation and Numbering of Sequences 

 
 

 2424-Requirements for Content of a “Sequence Listing” Part of the Specification under WIPO ST.25. 
 2424.01-Informational Requirements for the “Sequence Listing” 

 2424.02-“Sequence Listing” Numeric Identifiers 

 2424.03-Additional Miscellaneous Requirements 

 
 

 2425-Form and Format for a Nucleotide and/or Amino Acid Sequence Submission as an ASCII Plain Text File under WIPO ST.25 

 2426-Amendments to Add or Replace a “Sequence Listing” and CRF Copy Thereof Subject to WIPO ST. 25 

 2427-Form Paragraphs for Applications Subject to WIPO ST.25 

 2428-Sample Statements under WIPO ST.25 

 2429-Helpful Hints for Sequence Rules Compliance under WIPO ST.25 

 2430-PatentIn Information 

 2431-Sample “Sequence Listing” under WIPO ST.25 

 2432-[Reserved] 

 2433-Box Sequence; Hand Delivery of a “Sequence Listing” and Computer Readable Forms 

 2434-Examination of Patent Applications Claiming Large Numbers of Nucleotide Sequences 

 2435-Publishing of Patents and Patent Application Publications with a Lengthy “Sequence Listing” 

 

 

 
 

 
 
 

 
 

 

 
 
 Accessibility 

 Privacy Policy 

 Terms of Use 

 Security 

 Emergencies/Security Alerts 

 Information Quality Guidelines 

 
 

 
 
 Federal Activities Inventory Reform (FAIR) Act 

 Notification and Federal Employee Antidiscrimination and Retaliation (NoFEAR) Act 

 Budget & Performance 

 Freedom of Information Act (FOIA) 

 
 

 
 
 Department of Commerce NoFEAR Act Report 

 Regulations.gov 

 STOP!Fakes.gov 

 Department of Commerce 

 USA.gov 

 
 

 
 
 Strategy Targeting Organized Piracy (STOP!) 

 Careers 

 Site Index 

 Contact Us 

 Submit Feedback 

 
 

 
 This page is owned by Patents.

 Last Modified: 
 
 03/09/2026 20:50:46